Philip Morris Stock Price, News & Analysis

Philip Morris International (PM) reported strong 2024 results with adjusted diluted EPS of $6.57, representing 9.3% growth (15.6% currency-neutral). The smoke-free business showed remarkable performance with net revenues increasing by 14.2% and gross profit up 18.7% for the full year.

Key highlights include smoke-free product shipments exceeding 40 billion units quarterly for the first time, with the segment accounting for 40% of total net revenues. The company reached 38.6 million estimated adult users of smoke-free products (up 5.3 million from 2023) across 95 markets. IQOS strengthened its position as the second-largest nicotine brand, while ZYN nicotine pouches showed significant growth, particularly in the U.S.

For 2025, PMI forecasts reported diluted EPS of $6.55-$6.68, with adjusted diluted EPS growth of 7.2-9.1%. The company expects total shipment volume growth up to 2%, driven by smoke-free products growth of 12-14%, and organic net revenue growth of 6-8%.

Philip Morris International (NYSE: PM) has announced it will host a live audio webcast to discuss its 2024 Fourth-Quarter and Full-Year financial results on Thursday, February 6, 2025, at 9:00 a.m. ET. The financial results will be released at approximately 7:00 a.m. ET the same day.

The webcast will feature CEO Jacek Olczak and CFO Emmanuel Babeau, including a Q&A session with investors. The listen-only event will be accessible via PMI's website and Investor Relations App, with recordings available until March 7, 2025.

As of June 30, 2024, PMI's smoke-free products were available in 90 markets, with an estimated 36.5 million adult users worldwide. The smoke-free business represented approximately 38% of PMI's total first-nine months 2024 net revenues. Since 2008, PMI has invested over $12.5 billion in developing smoke-free products, including the acquisition of Swedish Match in 2022, creating a global smoke-free portfolio led by IQOS and ZYN brands.

Philip Morris International (NYSE: PM) commissioned a multinational survey revealing strong public belief in innovation's potential to address critical issues. The survey, conducted by Povaddo across 10 countries, shows that 76% of people are excited about technology's opportunities, while 74% agree that debate on innovations is polarized.

Key findings include that 71% believe innovation can enable vaccine development, and 62% think it can ensure affordable healthcare. However, only 49% believe in innovation's capacity to reduce smoking rates. The survey highlights significant challenges, with 80% of respondents citing misinformation as a barrier to progress, and 64% worried about the rapid pace of technological change.

Citizens strongly support government action, with 90% emphasizing the importance of ensuring public access to accurate information and establishing clear regulations. Additionally, 87% want governments to tackle misinformation, and 83% support public-private sector collaboration.

Philip Morris International (NYSE: PM) announced that the FDA has authorized all ZYN nicotine pouch products, making ZYN the first and only authorized nicotine pouch in the United States. The authorization covers 20 different products across 10 flavors (Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth, Chill, and Menthol) in both 3mg and 6mg strengths.

The FDA's decision recognizes ZYN's potential role in public health protection by providing alternatives to approximately 45 million Americans who regularly consume nicotine, including 30 million smokers. Swedish Match N.A., a PMI subsidiary, emphasizes responsible marketing practices, including age verification systems and restrictions to adults 21+. The company is also a member of the We Card Program and TruAge® to ensure strict age verification compliance.

Philip Morris International (NYSE: PM) has declared a regular quarterly dividend of $1.35 per common share, payable on January 13, 2025, to shareholders of record as of December 26, 2024. The company has invested over $12.5 billion since 2008 in developing smoke-free products, which now account for approximately 38% of total revenues in the first nine months of 2024. PMI's smoke-free products are available in 90 markets with an estimated 36.5 million adult users globally. The company's portfolio includes the IQOS and ZYN brands following its acquisition of Swedish Match, positioning PMI as a global smoke-free champion.

Philip Morris International (PMI) celebrates the 10th anniversary of IQOS, its leading smoke-free product. Since IQOS's launch in Japan in 2014, the country has seen a 46% decrease in cigarette-smoking prevalence, dropping from 19.6% to 10.6% in 2022. IQOS now generates over $10 billion of PMI's annual net revenues and is available in over 70 markets with 30.8 million adult users. Smoke-free products account for 38% of PMI's net revenues in Q3 2024, up from nearly zero in 2014. The company has invested over $12.5 billion in developing and commercializing smoke-free products since 2008.

The FDA has renewed the modified risk tobacco product (MRTP) authorization for eight General snus products from Swedish Match, a Philip Morris International (PM) affiliate. This renewal allows Swedish Match to market these products as lower-risk alternatives to cigarettes. The authorization was based on 330 scientific studies, including epidemiological research from Sweden, which has one of the world's lowest smoking rates. The products can be marketed with claims that using General snus instead of cigarettes reduces the risk of various tobacco-related diseases. This marks a significant milestone as PMI affiliates have now secured 13 of the 16 MRTP authorizations granted by the FDA.

Philip Morris International (PMI) reported strong Q3 2024 results, raising its full-year guidance. Key highlights include:

- Reported Diluted EPS grew 49.2% to $1.97
- Adjusted Diluted EPS increased 14.4% to $1.91
- Smoke-free business accounted for 38% of total net revenues and 40% of gross profit
- IQOS HTU adjusted in-market sales volume up 14.8%
- ZYN nicotine pouch shipments in the U.S. grew 41.4% to 149.1 million cans
- Combustibles net revenues grew 5.2% (8.6% organically)

PMI raised its 2024 full-year guidance for reported diluted EPS to $6.20-$6.26 and adjusted diluted EPS to $6.45-$6.51. The company expects 14-15% growth in adjusted diluted EPS excluding currency impacts.

Philip Morris International (PMI) has been informed of a proposed plan to resolve tobacco product-related claims and litigation in Canada. The plan, filed by a court-appointed mediator, involves PMI's deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), along with two other tobacco companies. Under the proposal, the companies would pay an aggregate settlement of CAD 32.5 billion (approximately USD 23.5 billion).

The settlement would be funded through upfront payments and annual contributions based on the companies' net income. If approved and implemented, the plan would release claims against RBH and its affiliates, including PMI, related to tobacco products. PMI CEO Jacek Olczak welcomed this step towards resolving long-pending litigation in Canada.

If RBH is reconsolidated, it is expected to be incremental to PMI's key financial metrics. The plan remains subject to further negotiation, court orders, voting by claimants, and court approval. Voting is proposed for December 2024, with a potential approval hearing in the first half of 2025.